regn5381
mAbexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2020 (NCT04506645)
Timeline
Indications
Mechanism of action
NPR1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06833190 | Phase 2 | Apr 16, 2025 | Regeneron |
| NCT06237309 | Phase 2 | Apr 11, 2024 | Regeneron |
| NCT05353166 | Phase 2 | Jun 30, 2022 | Regeneron |
| NCT05291546 | Phase 1 | Apr 13, 2022 | Regeneron |
| NCT04506645 | Phase 1 | Sep 1, 2020 | Regeneron |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Regeneron | For profit | 5 | 5 | 2 | 2020 |
1 organizations
Page 1 / 1